Sector News

Transforming clinical trials during COVID-19

April 14, 2020
Life sciences

We all know that most life sciences companies are working and collaborating tirelessly to develop tests and treatments for COVID-19. The importance and scope of that work cannot be overstated – it must take precedence as this crisis unfolds.

At the same time, though, life sciences companies must also advance the treatments in their pipelines that are essential for so many other human health issues. This is critical to navigate the immediate crisis and emerge stronger in a new normal.

Continuing to progress treatments across clinical phases, while taking care of patients who are currently in clinical trials and depend on the therapy, is vital to world health and scientific progress.

Now more than ever, the industry needs to leverage the power of data, analytics and remote engagement at scale to improve how the clinical trials are run.

At Accenture, we have been talking to our clients about what to do now, in the near-term and then what to do next to transform their clinical trial processes.

Right now, life sciences companies need to engage, empower and enable patient access to clinical trials. That means leverage call centers and virtual methods to empower patients and provide information or access to clinical trials, care and investigational therapies.

Life sciences companies should also assess other areas that are experiencing disruption including getting the necessary clinical supplies to patients and alternative ways to deliver treatments that don’t require in-person meetings. Obviously, it is imperative to balance compassionate use for non-trial eligible patients and those who have stopped a trial with safety considerations. It is also important to apply Health Authority guidance to maintain consistency in running clinical trials to assure safety, good clinical practice (GCP) compliance and trial integrity.

In the near term, it is essential to rationalise clinical trial priorities and “lean on” virtual. This means redefining clinical trial prioritization based on unmet patient need, study progress, supplies availability, and business objectives. Rationalise portfolios and reallocate resources, respecting the balance of trial sites’ bandwidth against portfolio demands.

At the same time, it’s equally important to assess the protocols for remote-patient monitoring, making sure they are both useful and feasible.

The next, longer-term step is for life sciences companies to rethink the clinical trial experience, how to humanise this experience and then build it across multiple trial sites.

To do this, they need to reimagine the clinical trial experience by proactively co-creating the trial design with patients and taking a 360-degree view of the dimensions of their lives…as people.

Must-haves for life sciences companies include digital capabilities for remote-enabled trials to build resiliency into operations and care continuity. They should also prioritise creating full-scale digital capabilities that can speed time-to-insights for decision making and drastically reduce onsite burden. Finally, they should re-examine where to hold clinical trials and the selection of alliance sites and service providers.

COVID-19 has shed light on the need to ensure that clinical trials continue, no matter what the circumstances. Continuing to progress treatments across clinical phases is a need that can be met with careful planning and the courage to embrace a new, more digital, more human way of serving patients in clinical trials.

Stuart Henderson is a senior managing director leading Accenture’s Life Sciences business

Source: Pharma Times

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach